12 Dec , 2024 By : Debdeep Gupta
Gland Pharma's share price rose 2 percent in the opening trade on December 12 after the company received approval from the United States Food and Drug Administration (USFDA) for Phytonadione Injectable Emulsion USP, 10 mg/mL single-dose ampules.
At 09:21 am, Gland Pharma was quoting at Rs 1,823.70, up Rs 48.35, or 2.72 percent, on the BSE.
The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Vitamin KI Injectable Emulsion USP, 10 mg/mL, of Hospira, Inc.
This product is indicated in coagulation disorders caused by vitamin K deficiency or interference with vitamin K activity.
The company expects to launch this product through its marketing partners shortly.
Earlier this month, the company received USFDA approval for Latanoprost Ophthalmic Solution, 0.005%, which is used for the treatment of high eye pressure/intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
The company's consolidated Q2FY25 profit declined 15.7 percent to Rs 163.5 crore, while revenue grew 2.4 percent to Rs 1,405.8 crore, YoY.
0 Comment